Search Results

You are looking at 91 - 100 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease (mainly epithelial ovarian cancer), and 6) management of drug/hypersensitivity reactions. 1

Full access

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes

NSCLC, including pembrolizumab monotherapy, pembrolizumab/chemotherapy, and atezolizumab/bevacizumab/chemotherapy. 13 – 20 These NCCN Guidelines Insights focus on recent updates in immunotherapy for eligible patients with metastatic NSCLC. Furthermore

Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

hand, the prospective, multicenter phase II NSABP C-10 trial showed that patients with an asymptomatic primary colon tumor and unresectable metastatic disease who received mFOLFOX6 with bevacizumab experienced an acceptable level of morbidity without

Full access

Paul F. Engstrom

that FOLFOX for 6 months was superior to 5-FU/leucovorin as adjuvant therapy for patients with stage III colon cancer. 1 In 2004, antibody therapy of colon cancer became a reality with the discovery that bevacizumab selectively inhibited tumor

Full access

Lina Jansen, Daniel Boakye, Elizabeth Alwers, Prudence R. Carr, Christoph Reissfelder, Martin Schneider, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

therapy (eg, bevacizumab for stage IV CRC). Some of these innovations (eg, targeted therapy) are associated with major increases in costs, 5 and their implementation may vary according to health insurance coverage. Meta-analyses of clinical trials

Full access

John G. Phillips, Theodore S. Hong, and David P. Ryan

microenvironment and tumor cell type–specific effects. 38 Bevacizumab is an anti-VEGF monoclonal antibody initially developed in colorectal cancer. Increased VEGF levels in colorectal cancers have been shown to predict poor outcomes. 39 , 40 Bevacizumab

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

December 2005, 6 new drugs have been approved by the FDA for the treatment of metastatic RCC. The currently available targeted agents can be classified as VEGF-pathway targeting agents (bevacizumab, sunitinib, sorafenib, and pazopanib) and mTOR

Full access

Benjamin A. Weinberg

bevacizumab in patients with KRAS exon 2 wild-type mCRC, the longest overall survival was seen in the study arm that included patients with left-sided tumors treated with cetuximab (36.0 months), followed by the left-sided tumors treated with bevacizumab arm

Full access

Harold J. Burstein

specifically recommended against in the NCCN Guidelines because they were known to be ineffective or to lack any efficacy data. These included bevacizumab beyond progression with bevacizumab, capecitabine after fluoropyridimidine regimens, and panitumumab or

Full access

subsequent therapy of kidney cancer with predominant clear cell histology, the category for bevacizumab was changed from a category 2B to category 2A following cytokine therapy and category 2B following tyrosine kinase inhibitor. For systemic therapy of